ClinicalTrials.gg
RecruitingNCT06968559DEXA-BURNUpdated Nov 18, 2025

Effect of Early Dexamethasone on Major Complications and All-cause Mortality in Severe Burns

A Phase 3 interventional study of Dexamethasone and Placebo in Severe Burns, sponsored by Nantes University Hospital. Recruiting at 10 sites in France. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2025-11-18.

Sponsored by Nantes University Hospital · Phase 3, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Nov 2025; still recruiting 1 year later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
478
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 32 studies in Burns with a site in France — 6 open to participants now, 7 under way, 2 of them phase 3. Burns · France.

Planned enrollment
2nd of 22
478 · median 27
Started
2025
with 2 others
Phase 3
6 of 32
2 open now
Registered
31st of 32
by date
Lead sponsor
2 of 32
Nantes University Hospital

Among the 32 studies in Burns with a site in France, this one is the 2nd largest by planned enrollment of the 22 interventional ones that give a count, is one of 3 that started in 2025, is one of 6 in phase 3, and was the 31st registered.

Burns

906 studies on the registry are indexed under Burns; 165 are open to participants now.

Browse Burns studies →

Open to participants now

6 of the 32 studies in Burns with a site in France are open now. Recruiting first, the newest first:

All 6 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 87 Burns studies recruiting now, 38 (44%) set no upper age limit and 38 (44%) stop at 75 or younger; 17 take children under 18; 10 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 32 studies in Burns with a site in France, or all of them as a file.
02

Study summary

Burns affect more than 11 million people worldwide each year. These injuries are responsible for severe morbidity resulting in a high societal burden and account for more than 180,000 yearly deaths especially in low- and middle-income countries.

Major burns induce an important local and systemic inflammatory response that may be overwhelmed. This inflammation is a physiological phenomenon that favours the healing of tissues. However, the overproduction of inflammatory mediators might lead to an exacerbated Systemic Inflammatory Response Syndrome (SIRS). Recently the total body surface area (TBSA) burned has shown to be well correlated to persistent elevation of pro-inflammatory mediators (such as IL-6). This SIRS, in turn, contributes to the enhanced risk of sepsis, acute respiratory distress syndromes (ARDS) and organ failures in general such as acute kidney injuries (AKI), most of those occurring within the first week of admission.

Corticosteroids (CS) have already proven their effectiveness against SIRS-induced organ dysfunction or mortality in acute medicine notably in septic shock, polytraumatized patients and more recently in the treatment of viral or non-viral ARDS without increasing the risk of secondary bacterial complications or significant side effects . Indeed the recent SCCM Guidelines clearly advocate for the use of CS in severe community-acquired pneumonia, septic shock and ARDS. The investigators recently performed a large multicenter, double-blinded randomized controlled trial (the PACMAN trial, PHRC-N 2016) including 1222 patients scheduled for major surgery in which the investigators observed a major decrease in CRP blood concentrations in the dexamethasone arm. The rate of AKI and the need for mechanical ventilation were also significantly reduced in the intervention arm. ICU Patients with severe burns undergo several surgeries, including major procedures (excision, skin grafts), rendering them quite similar to those in the PACMAN trial in terms of inflammatory response. Very few side effects (hyperglycemia mainly) easily overcome in ICU are usually reported with the use of low-to-moderate dose of CS.

In severe burn patients, very few data are available to date, two retrospective case control studies and a small prospective randomized trial showed promising results when using CS but high quality evidence is lacking.

The investigators hypothesise here that the use of dexamethasone after major burns, the prototypic model of inflammatory response in surgical ICU patients, would limit SIRS-induced organ failure and/or all-cause mortality.

03

Conditions studied

  • Severe Burns

Browse trials for

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 18 years old ≤ Age ≤ 80 years old.
  • Total burn surface area ≥ 20%, measured by a trained expert upon admission
  • Invasive mechanical ventilation at the time of inclusion
  • Within 48 hours of the burn injury
  • Informed and signed written consent of the next-of-kin, legal representative (trusteeship, guardianship) or emergency procedure in the absence of a legal representative.
  • Affiliation with French social security system or beneficiary from such system

Exclusion criteria

Exclusion Criteria:

  • Imminent death and a do-not-resuscitate order

    • Medical history of to dexamethasone and hypersensitivity to all of its
    • Pregnancy (attested by a pregnancy test for women of childbearing age) and/or breastfeeding women
    • Participation to another interventional study involving a drug with known interactions with dexamethasone
    • Uncontrolled viral hepatitis or invasive fungal infection at the time of inclusion
    • Prolonged administration of in the last 90 days (>0.3 mg/kg/day of equivalent prednisolone)
    • Moderate-to-severe ARDS upon admission (according to Berlin definition criteria)
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
478 participants (estimated)

Study arms

  • Experimental
    Dexamethasone

    Dexamethasone 0.2 mg/kg of ideal body weight (IBW) IV (at a maximum of 20 mg per day) will be blindly infused from day 1 to day 5

    Drug: Dexamethasone

  • Placebo comparator
    Placebo

    Placebo: one IV administration per day from day 1 to day 5.

    Drug: Placebo

Interventions

  • Dexamethasone 0.2 mg/kg of ideal body weight (IBW) IV (at a maximum of 20 mg per day) will be blindly infused from day 1 to day 5;

  • DrugPlacebo

    Placebo: one IV administration per day from day 1 to day 5.

06

What researchers measure

Primary outcomes

  1. Major complications

    It's a hierarchic procedure. Major complications defined as moderate to severe ARDS (using Berlin definition criteria) or AKI KDIGO 2 to 3 within 28 days

    Time frame: 28 days

  2. All-cause mortality at day 90

    Time frame: 90 days

Secondary outcomes

  1. Hospital-acquired infections

    Hospital-acquired pneumonia (using the joint definition from the Infectious Diseases Society of America and American Thoracic Society) within 28 days

    Time frame: 28 days

  2. Hospital-acquired infections

    Catheter-related bloodstream infections within 28 daysDiseases Society of America and American Thoracic Society) within 28 days

    Time frame: 28 days

  3. Hospital-acquired infections

    other infections, including skin infections (diagnosis confirmed by an independent adjudication committee) with or without bacteraemia within 28 days

    Time frame: 28 days

  4. Hospital-acquired infections

    Antibiotic-free days on day 28

    Time frame: 28 days

  5. Respiratory complications

    ARDS (using Berlin Criteria definition) on day 28

    Time frame: 28 days

  6. Respiratory complications

    Invasive ventilator-free days on day 28

    Time frame: 28 days

  7. ICU Length-of-Stay

    ICU Length-of-Stay

    Time frame: 28 days

  8. Hospital Length-of-Stay

    Hospital Length-of-Stay

    Time frame: 28 days

  9. risks of organ dysfunction

    SOFA scores

    Time frame: 14 days

  10. risks of organ dysfunction

    KDIGO stages 2 and 3 AKI

    Time frame: 28 days

  11. General tolerance of the treatment

    Number of Participants with Hyperglycemia

    Time frame: 28 days

  12. specific tolerance of the treatment on skin lesions

    surgical site infections confirmed by an independent adjudication committee,

    Time frame: 28 days

  13. Timing of first surgery

    Timing of first surgery on the main endpoint

    Time frame: 28 days

  14. Impact of treatment on serum CRP Levels

    Serum CRP levels on day 0, day 1, day 3, day 7 and day 14

    Time frame: 14 days

  15. General tolerance of the treatment

    Number of Participants with hypernatremia

    Time frame: 28 days

  16. General tolerance of the treatment

    Number of Participants with hypokalaemia

    Time frame: 28 days

  17. General tolerance of the treatment

    Number of Participants with gastrointestinal bleeding

    Time frame: 28 days

  18. General tolerance of the treatment

    Number of Participants with acquired-weakness

    Time frame: 28 days

07

Study locations

1 of 10 sites recruiting
08

References and documents

Publications

  • Bourdiol A, Bruder N, Depret F, Flattres D, Flet L, Fortin J, Gaufichon AE, Glavnik B, Jeanne M, Jobert A, Jung B, Lukaszewicz AC, Mathelier N, Pere M, Pichon X, Ravaux H, Mahe PJ, Asehnoune K; DEXA-BURN study group. Effect of early dexamethasone on major complications and all-cause mortality in severe burns (DEXA-BURN): study protocol for a multicenter, randomized, placebo-controlled, double-blind trial. Trials. 2026 Jun 24. doi: 10.1186/s13063-026-09869-z. Online ahead of print. PubMed 42337788 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2025 (actual). Primary completion is estimated for Feb 2029, 39 months after the start.

Of 21 phase 3 interventional studies under Burns, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 59. This study's planned 39 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 22, 2025
First posted
May 13, 2025
StartActual
Nov 7, 2025
Primary completionEst.
Feb 7, 2029
CompletionEst.
Feb 7, 2029
Last update
Nov 18, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 18, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06968559
Responsible party
Sponsor
First posted
May 13, 2025
Start date
Nov 7, 2025
Primary completion
Feb 7, 2029 (estimated)
Completion
Feb 7, 2029 (estimated)
Last update
Nov 18, 2025

Study contacts

Karim ASHENOUNE, MD, PhD
Contact
karim.asehnoune@chu-nantes.fr
+33 (0)2 53 482 835
Alexandre BOURDIOL, PH
Contact
alexandre.bourdiol@chu-nantes.fr
+33 (0)2 53 482 217

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dexamethasone

Start the discussion